Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04440683

Enrollment

6000

Registered

2020-06-22

Start date

2020-06-30

Completion date

2025-06-30

Last updated

2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Prevention

Brief summary

This study aims to prove whether antler disk extract can be put into clinical practice to prevent breast precancerous lesions from developing into cancer.

Detailed description

Through estrogen receptor antagonists, tamoxifen can reduce the risk of breast high-risk disease progression to cancer, but only reduce the probability of some ER and PR positive tumors, which has no preventive effect on triple negative breast cancer and HER-2 positive breast cancer. In the first hospital of Jilin University, the preparations containing antler ingredients have been clinically proven to be able to treat breast hyperplasia, which has been proved to be able to prevent breast cancer in basic research, and antler ingredients have been proved to be non-toxic and side effects in the treatment dose. This study aims to prove whether antler disk extract can be put into clinical practice to prevent breast precancerous lesions from developing into cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Women between the ages of 18 and 80 * Atypical hyperplasia or / and lobular carcinoma in situ confirmed by breast histology * Women with breast cancer in first degree relatives * Patients have better compliance with a series of research-related behaviors such as the upcoming comprehensive treatment and follow-up, and can understand and accept the research process of this study, and sign a written informed consent

Exclusion criteria

* Hepatorenal dysfunction, cardiovascular and cerebrovascular diseases * Patients not suitable for this study judged by researchers

Design outcomes

Primary

Measure	Time frame	Description
Canceration by biopsy	1 year	Imaging suspected malignant, confirmed by pathology

Countries

China

Contacts

Primary ContactDi Wu, Doctor

w2000mail@sohu.com0086-13504331975

Backup ContactHongyao Jia, Master

52272435@qq.com0086-1580430156

Outcome results